Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER.
Ther Innov Regul Sci
; 2022 Dec 02.
Article
in English
| MEDLINE | ID: covidwho-2323759
ABSTRACT
The Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) have been leaders in protecting and promoting the U.S. public health by helping to ensure that safe and effective drugs and biological products are available in the United States for those who need them. The null hypothesis significance testing approach, along with other considerations, is typically used to demonstrate the effectiveness of a drug or biological product. The Bayesian framework presents an alternative approach to demonstrate the effectiveness of a treatment. This article discusses the Bayesian framework for drug and biological product development, highlights key settings in which Bayesian approaches may be appropriate, and provides recent examples of the use of Bayesian approaches within CDER and CBER.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
S43441-022-00483-0
Similar
MEDLINE
...
LILACS
LIS